Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859504 | 0.91 | CYP1A2 (0.57) | LMNACYP4F2CYP4A11KDM4EMAPT | |
| SCHEMBL2964336 | 0.89 | CYP4F2 (0.57) | LMNACYP4F2CYP4A11KDM4EMAPT | |
| SCHEMBL11532136 | 0.88 | TDP1 (0.55) | LMNACYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL6646352 | 0.88 | CYP4F2 (0.56) | LMNACYP4F2CYP4A11KDM4EMAPT | |
| SCHEMBL10260884 | 0.86 | POLB (0.55) | LMNAKDM4EMAPTCYP2C19SMN1; SMN2 | |
| SCHEMBL11532390 | 0.85 | CA12 (0.58) | LMNACYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| Ethylene Glycol SCHEMBL11535308 | 0.84 | TDP1 (0.50) | LMNACYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL11531289 | 0.84 | NAAA (0.53) | LMNACYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL134991 | 0.83 | LMNA (0.56) | LMNAKDM4ECYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2769178 | 0.83 | SMN1; SMN2 (0.52) | LMNAKDM4ECYP1A2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| CN-110903306-B | Muscarinic receptor agonists | 赫普泰雅治疗有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3271358-B1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| EP-3271358-B1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| EP-0694546-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | disclosed |
| EP-0694545-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | disclosed |
| US-5464830-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5378840-A | Substituted dibenzoxazepine compounds | G. D. SEARLE & CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0583421-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1994-02-23 | — | — | EP | disclosed |
| WO-1992019617-A2 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512400-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
| US-4216318-A | HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| US-4154834-A | HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
| US-4153795-A | Cobalt pyridyl catalysts for hydroformylation | DIRECTOR-GENERAL OF THE AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885CYP4F2 1232/4885CYP4A11 496/4885 |
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885CYP4F2 1232/4885CYP4A11 496/4885 |
| US-11034704-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885CYP4F2 1232/4885CYP4A11 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.